Tabla de Contenidos:
  • Intro
  • The Gut Microbiota in Health and Disease
  • Contents
  • List of Contributors
  • 1 Structural and Dynamics of Healthy Adult's Microbiota
  • 1.1 Introduction
  • References
  • 2 Composition and Diversity of Gut Microbiota
  • 2.1 Introduction
  • 2.2 Composition and Diversity of Gut Microbiota Throughout Lifespan
  • 2.3 Composition of Bacterial Community in the Different Sections of the Gastrointestinal Tract
  • 2.4 Stability, Resilience, and Functional Redundancy
  • 2.5 Interactions in the Gut Microbiota
  • 2.5.1 Microbe-microbe Interactions
  • 2.5.2 Host-microbe Interactions
  • 2.5.3 Colonisation of the Gut Microbiota
  • 2.6 Conclusion
  • References
  • 3 Factors Affecting Composition and Diversity of Gut Microbiota: A Disease Hallmark
  • 3.1 Introduction
  • 3.2 Composition of Gut Microbiota
  • 3.2.1 Gut Microbiota of Infants and Newborns
  • 3.2.2 Gut Microbiota of Adults
  • 3.3 Factors Affecting Gut Microbiota
  • 3.3.1 Age and Delivery Pattern
  • 3.3.2 Diet
  • 3.3.3 Antibiotics
  • 3.3.4 Oxidative Stress
  • 3.4 Modulation of Gut Microbiota
  • 3.4.1 Probiotics and Prebiotics
  • 3.5 Gut Microbiota Hallmark in Disease Condition
  • 3.5.1 Cancer
  • 3.5.2 COVID-19
  • 3.5.3 HIV
  • 3.6 Conclusion
  • References
  • 4 Antibiotic-Induced Changes in the Composition of the Gut Microbiome
  • 4.1 Introduction
  • 4.2 Gut Microbiota Composition
  • 4.3 Antibiotic-induced Changes in the Composition of the Microbiota
  • 4.3.1 Loss of Bacterial Diversity and Domination of Pathogenic Bacteria
  • 4.3.2 Decrease or Loss of Certain Bacterial Species
  • 4.3.3 Increase in Susceptibility to Infections and Diseases
  • 4.4 Conclusion
  • References
  • 5 Dysbiosis and its Varied Impacts
  • 5.1 Introduction
  • 5.2 Causes of Dysbiosis
  • 5.3 Dysbiosis, Immune System, and Associated Diseases
  • 5.3.1 Dysbiosis in the Immune-Compromised Host.
  • 5.3.2 Intestinal Bowel Disease (IBD)
  • 5.3.3 Rheumatoid Arthritis
  • 5.3.4 Type 1 Diabetes
  • 5.3.5 Dysbiosis of Skin Microbiome in Carcinogenesis
  • 5.3.6 Dysbiosis of Oral Microbiota Impacts Carcinogenesis
  • 5.3.7 Dysbiosis of Urobiome
  • 5.3.8 Pigmented Gallstone
  • 5.3.9 Cholangitis
  • 5.4 Intestinal Colonisation in Neonates and Dysbiosis
  • 5.5 Treatment or Therapeutics
  • 5.6 Conclusion
  • References
  • 6 Connection between Dysbiosis and Diet
  • 6.1 Introduction
  • 6.1.1 Gut Microbiota and Dysbiosis
  • 6.1.2 Importance of Diet in regulation of Gut Microbiota
  • 6.2 Different Dietary Patterns Resulting in Dysbiosis
  • 6.2.1 Breastfeeding
  • 6.2.2 Carbohydrate-rich Diet
  • 6.2.3 Protein-rich Diet
  • 6.2.4 Fats and Oil-rich Diet
  • 6.3 Future Prospects in Establishing a Healthy Connection between Diet and Gut Microbiota
  • 6.4 Conclusion
  • References
  • 7 Composition of Gut Microbiota and Clostridium difficile
  • 7.1 Introduction
  • References
  • 8 Gut Microbiota and Obesity
  • 8.1 Introduction
  • 8.2 Obesity Epidemic: Statistics and General Background
  • 8.3 Gut Microbiota and Obesity
  • 8.4 Adiposity and Gut Microbiota
  • 8.4.1 Short Chain Fatty Acids (SCFAs)
  • 8.4.2 AMPK and FIAF
  • 8.4.3 Bile Acids
  • 8.4.4 Lipopolysaccharides (LPS)
  • 8.5 Gut Microbiota Modification
  • 8.5.1 Diet
  • 8.5.2 Age
  • 8.5.3 Antibiotics
  • 8.5.4 Probiotics
  • 8.6 The Microbiota and Obesity Interactions
  • 8.6.1 Immune System
  • 8.6.2 Lipid Metabolism
  • 8.6.3 Satiety Hormones
  • 8.6.4 Nutrient Metabolism
  • 8.6.5 Lymphoid Structures
  • 8.6.6 Microbiota-Adipose Tissue Axis
  • References
  • 9 Gut Microbiota and Cardiovascular Disease
  • 9.1 Introduction
  • 9.2 Gut Microbiota and CVD
  • 9.2.1 Role of TMAO in Coronary Heart Disease
  • 9.3 Gut Microbiota Composition in Cardiovascular Disease
  • 9.4 Gut Microbiota Function in Cardiovascular Disease.
  • 9.5 Gut Microbiota as Therapeutic Strategies for Cardiovascular Disease
  • 9.5.1 Probiotics
  • 9.5.2 Fecal Microbiota Transplantation
  • References
  • 10 Gut Microbiota and Inflammatory Bowel Diseases
  • 10.1 Introduction
  • 10.2 Intestinal Microbiome in IBD Patients
  • 10.2.1 Dysbiosis in IBD
  • 10.2.2 Genetic Factors of the Host Affecting the Pathogenesis of IBD
  • 10.2.3 Environmental Factors in the Disruption of Gut Microbiota and Development of IBD
  • 10.3 Interventions for the Treatment of IBD
  • 10.3.1 Microbiome-modulating Approach in the Treatment of IBD
  • 10.4 Conclusion
  • References
  • 11 Gut Microbiota and Diabetes
  • 11.1 Introduction
  • 11.2 Gut Microbiota
  • 11.3 Role of Gut Microbiota in Diabetes
  • 11.4 Alteration in Gut Microbiota Composition in T1 and T2 Diabetes
  • 11.4.1 T1D
  • 11.4.2 Type 2 Diabetes
  • 11.5 Diabetic Complications
  • 11.5.1 Diabetic Retinopathy
  • 11.5.2 Diabetic Nephropathy
  • 11.5.3 Diabetic Neuropathy
  • 11.6 Therapeutic Approaches
  • 11.7 Conclusion
  • References
  • 12 Novel Therapeutic Strategies Targeting Gut Microbiota to Treat Diseases
  • 12.1 Introduction
  • 12.2 Changes in the Composition of the Gut Microbiota in Patients with T1D
  • 12.3 The Potential Role of the Gut Microbiota in the Development of T1D
  • 12.4 Changes in the Composition of the Gut Microbiota in Patients with T2D
  • 12.5 The Potential Role of the Gut Microbiota in the Development of T2D
  • 12.7 Preventive and Therapeutic Perspectives Including the Gut Microbiota
  • References
  • 13 Understanding the Role of Microbiota in Cancer
  • 13.1 Introduction
  • 13.2 Role of Microbiota in Cancers
  • 13.2.1 Gastric Cancer
  • 13.2.2 Colorectal Cancer
  • 13.2.3 Liver Cancer
  • 13.2.4 Pancreatic Cancer
  • 13.3 Mechanism in which Microbiota Kill Cancer Cells
  • 13.4 Microbiota that Promote Health Post Cancer Treatment
  • 13.5 Conclusion.
  • References
  • 14 Impact of Gut Microbiota on Mental Health in Humans
  • 14.1 Introduction
  • 14.1.1 Importance of Gut Microbiota
  • 14.1.2 The Microbiota-Gut-Brain Axis
  • 14.2 Gut Dysbiosis and Mental Health Disorders
  • 14.2.1 Neurodevelopmental Disorders
  • 14.2.2 Mood Disorders
  • 14.2.3 Depression Disorders
  • 14.2.4 Alcohol Use Disorder (AUD)
  • 14.3 Psychiatric Medication and the Microbiome
  • 14.4 Probiotic Treatments for Mental Health Disorders
  • 14.5 Future Therapeutic Approach
  • 14.6 Conclusion
  • References
  • 15 Interaction between Gut Microbiota and Central and Enteric Nervous Systems: The Gut-Brain Axis Concept
  • 15.1 Introduction
  • 15.2 The Neuronal Communications
  • 15.3 Neuroimmune Regulation of Inflammation and Cellular Defence
  • 15.3.1 Involvement of Microbiota in the Development of the Nervous and Immune Systems and Modulation of Inflammation
  • 15.3.2 The Importance of Microbiota for the Development of the Nervous and Immune Systems
  • References
  • 16 Immune-Modulation and Gut Microbiome
  • 16.1 Introduction
  • 16.2 Dysbiosis of the Gut Microbiome
  • 16.3 Gut Dysbiosis and Diseases
  • 16.3.1 Inflammatory Bowel Disease
  • 16.3.2 Non-alcoholic Fatty Liver Disease
  • 16.4 Gut Microbiome-Mediated Immune Modulation
  • 16.4.1 Innate Immunity
  • 16.4.2 Adaptive Immunity
  • 16.5 Gut Microbiome Modulators
  • 16.5.1 Diet
  • 16.5.2 Diet, Gut Microbiome, and Immunity
  • 16.5.3 Short-Chain Fatty Acids
  • 16.6 Prebiotics
  • 16.7 Probiotics
  • 16.8 Galectins, Gut Microbiome, and Immune Modulation
  • 16.9 Conclusion
  • References
  • 17 Current Molecular Technologies for Assaying the Gut Microbiota: Next-generation DNA Sequencing
  • 17.1 Introduction and Overview
  • 17.2 Research on the Gut Microbiome Using Next-generation Sequencing
  • 17.2.1 Amplicon Sequencing
  • 17.2.2 Shotgun Metagenomic and RNA Sequencing.
  • 17.2.3 Comparisons between NGS Methods
  • 17.3 Collection, Storage, and DNA Extraction Methodology
  • 17.3.1 Sample Collection and Storage
  • 17.3.2 DNA Extraction and Quantification
  • 17.4 DNA Sequencing and Post-processing
  • 17.5 Metabolic Modelling of the Human Gut Microbiome
  • References
  • 18 The Role of Probiotics and Prebiotics in Gut Modulation
  • 18.1 Introduction
  • 18.2 Probiotics and Prebiotics: A Functional Perspective
  • 18.3 Diet and its Effect on Gut Microbiota
  • 18.4 Modification of Intestinal Microbiota by the Application of Probiotics and Prebiotics
  • 18.4.1 Dysbiosis and Human Diseases
  • 18.4.2 How Probiotics Alter the Intestinal Microbiota
  • 18.4.3 Probiotics and Intestinal Immunomodulation
  • 18.4.4 Probiotics and Prebiotics on Intestinal Neuroimmunology
  • 18.5 Prebiotics and Gut Immunity
  • 18.5.1 Effects (Direct and Indirect) of Prebiotics on the Immune System
  • 18.6 Conclusions and Future Research
  • References
  • 19 Probiotics, Prebiotics, and Synbiotics: A Potential Source for a Healthy Gut
  • 19.1 Introduction
  • 19.2 Prebiotics
  • 19.2.1 Types of Prebiotics
  • 19.2.2 Functioning of Prebiotics
  • 19.3 Probiotics
  • 19.3.1 Characteristics of Probiotics
  • 19.3.2 Mechanisms of Action of Probiotic Strains
  • 19.3.3 Applications of Probiotics
  • 19.4 Synbiotics
  • 19.4.1 Selection Criteria
  • 19.4.2 Mechanism of Action
  • 19.4.3 Therapeutic Actions
  • 19.5 Conclusion
  • References
  • 20 Current Status and Efficacy of Fecal Microbiota Transplantation for Patients Suffering from Irritable Bowel Syndrome
  • 20.1 Introduction
  • 20.2 Donor Selection
  • 20.3 Safety Issues of FMT for IBS
  • 20.4 Possible Mechanisms Underlying the Effects of FMT
  • 20.5 Conclusion and Perspective
  • References
  • Index
  • EULA.